Recent news on Imiglucerase For

Genzyme's combination gene therapy shows potential for CNS disease  -  25 May 2007
DrugResearcher.com,Genzyme has invested heavily in gene therapy in the last few years and already has four products on the market: Cerezyme (imiglucerase for injection) for

Genzyme Reports Significant Revenue and Earnings Growth in First ...  -  26 Apr 2007
WebWire (press release),Sales of Cerezyme® (imiglucerase for injection), the standard of care for patients with Type 1 Gaucher disease, grew 10 percent to $263.8 million,

Genzyme Reports Financial Results for Fourth Quarter of 2006 and ...  -  Feb 14, 2007
Oxfordshire Bioscience Network (press release),Sales of Cerezyme® (imiglucerase for injection) are expected to reach $1.060-$1.075 billion this year, compared with $1.0 billion in 2006.

Genzyme Announces Publication of Study Showing Impact of ...  -  Jan 15, 2007
DG NewsCerezyme (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of

Genzyme Announces Publication of Study Showing Impact of Cerezyme ...  -  Jan 16, 2007
PipelineReview.com (press release),Cerezyme (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of

Largest-ever Fabry study shows earlier treatment with (Pr ...  -  Jan 16, 2007
CNW Telbec (Communiqués de presse),These include Cerezyme(R) (imiglucerase) for the treatment of Type 1 and Type 3 Gaucher disease and Aldurazyme(R) (laronidase) for the treatment of MPS I,

Genzyme Announces Publication of Study and StemCells, Inc. Elects ...  -  Jan 16, 2007
Financial News USA (press release),Cerezyme® (imiglucerase for injection) significantly improves bone mineral density in patients with Type 1 Gaucher disease in a dose-dependent manner.

Genzyme drug helps bone in Gaucher disease  -  Jan 15, 2007
United Press International...long-term use of Cerezyme (imiglucerase for injection) significantly improves bone mineral density in this patient group in a dose-dependent manner.

Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude ...  -  Jan 10, 2007
Oxfordshire Bioscience Network (press release),Fourth-quarter sales of Cerezyme® (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $262 million, 13 percent greater

First Therapy Ever Approved in Canada for Ultra-Rare Form of ...  -  Dec 7, 2006
CNW Telbec (Communiqués de presse),Genzyme has developed PrFabrazyme(R) (agalsidase beta) for Fabry disease, PrCerezyme(R) (imiglucerase) for Type 1 and Type 3 Gaucher disease and, in ...

Genzyme Reports Strong Third-Quarter Financial Results  Oct 12, 2006
Sales of Cerezyme® (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $252.2 million, 6 percent greater than sales of ... -Yahoo! News (press release) Genzyme Reports Strong Third-Quarter Financial Results  Oct 12, 2006
Sales of Cerezyme(R) (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $252.2 million, 6 percent greater than sales of ... -Drug Newswire (press release), First Therapy Ever Approved in Canada for Ultra-Rare Form of ...  -  Dec 8, 2006
DG NewsGenzyme has developed PrFabrazyme® (agalsidase beta) for Fabry disease, PrCerezyme® (imiglucerase) for Type 1 and Type 3 Gaucher disease and,

Genzyme given green light to make kidney drug at Irish plant  Aug 14, 2006
...said it also plans to use the Waterford facility for additional capacity and security for the fill/finish of Cerezyme (imiglucerase for injection) – an ERT ... -In-PharmaTechnologist.com

Delivers Solid Earnings Growth Based on Strong Top-Line ...  Jul 18, 2006
Sales of Cerezyme® (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $254.0 million, 8 percent greater than sales of ... -Oxfordshire Bioscience Network

Genzyme Reports Second-Quarter Financial Results  Jul 12, 2006
Sales of Cerezyme(R) (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $254.0 million, 8 percent greater than sales of ... -Drug Newswire



Genzyme Reports Financial Results for the First Quarter of 2006  Apr 19, 2006
Sales of Cerezyme(R) (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $239.0 million compared with $226.0 million in the ... - Webbolt Business News

FDA Approves Genzyme's Myozyme(R) for All Patients with Pompe ...  Apr 28, 2006
Genzyme has developed Cerezyme® (imiglucerase for injection) for Type 1 Gaucher disease; Fabrazyme® (agalsidase beta) for Fabry disease; and, in ... - Yahoo! News

Genzyme Reports Financial Results for the First Quarter of 2006  Apr 19, 2006
Sales of Cerezyme® (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $239.0 million compared with $226.0 million in the ... - Yahoo! News

Genzyme's First-Quarter Sales Below Expectations  Apr 19, 2006
Though likely to continue growing only modestly in the future, sales of the flagship Cerezyme (imiglucerase for injection) for Type 1 Gaucher's disease hit ... - BioWorld Online (subscription)





Genzyme Launches Initiative to Assist the Development of ...  11 Apr 2006
Among the programs Genzyme sponsors is the Gaucher Initiative, a partnership with Project HOPE that brings Cerezyme® (imiglucerase for injection) therapy to ... - Yahoo! News



Genzyme Reports Financial Results for Fourth Quarter of 2005 and ...  Feb 15, 2006
Sales of Cerezyme® (imiglucerase for injection) are expected to reach $970-$980 million this year, compared with $932 million in 2005. ... - WebWire,

Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue  Jan 9, 2006
Fourth-quarter sales of Cerezyme(R) (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $232 million, 6 percent greater ... - MSN Money

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional